Ocular surface changes following oral anticholinergic use for overactive bladder

Sekeroglu M. A., Hekimoglu E., Tasci Y., Dolen I., Arslan U.

CUTANEOUS AND OCULAR TOXICOLOGY, vol.35, no.3, pp.218-221, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 3
  • Publication Date: 2016
  • Doi Number: 10.3109/15569527.2015.1077856
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.218-221
  • Hacettepe University Affiliated: Yes


Objective: To investigate the effect of oral solifenacin succinate on Schirmer I test results, tear break-up time (TBUT) and Ocular Surface Disease Index (OSDI) scores in overactive bladder (OAB) patients and to compare these results with those of healthy control subjects.Materials and methods: The female OAB patients who were prescribed oral solifenacin succinate 5mg/day (Group I, N=80) and age-matched healthy female subjects (Group II, N=40) were recruited for the study and underwent ophthalmological examination prior to oral treatment and after 4 weeks. They completed the OSDI questionnaire and underwent ocular surface tests including Schirmer I test and TBUT.Results: The statistical analysis of the Schirmer I test and TBUT revealed no significant difference between the baseline and 4th week values in both groups (Group I, p=0.506 and p=0.070 consecutively) (Group II, p=0.810 and p=0.823 consecutively). OSDI scores were found to be significantly increased in group I (21.84.2 vs 23.1 +/- 4.6, p=0.020) and remained unchanged in group II (20.5 +/- 7.0 vs 20.7 +/- 7.0, p=0.805).Conclusions: Short-term solifenacin succinate treatment has no effect on the Schirmer I test results and TBUT, but ocular surface symptoms appeared to be exacerbated in respect with increased OSDI scores. However, the clinical significance needs to be further evaluated with larger studies.